Nanoantagonists with nanophase-segregated surfaces for improved cancer immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Peptide antagonists targeting PD-1/PD-L1 interactions can enhance anti-cancer immunity.
• Peptides suffer from low proteolytic stability, limiting their therapeutic efficacy.
• Developing stable and effective peptide-based cancer immunotherapies remains a challenge.

Purpose of the Study:

• To design a nanoantagonist with enhanced stability and efficacy for PD-1/PD-L1 immune checkpoint blockade.
• To improve the blood circulation and systemic stability of peptide antagonists.
• To evaluate the in vitro and in vivo performance of the nanoantagonist in cancer immunotherapy.

Main Methods:

• Fabrication of a nanoantagonist using an Au nanorod core coated with thermosensitive polymers.
• Creation of a nanophase-segregated surface sensitive to physiological temperature.
• Assessment of peptide stability, protein adsorption resistance, and PD-1/PD-L1 blockade efficacy.
• In vitro and in vivo evaluation of anti-tumor immune response and tumor growth inhibition.

Main Results:

• The nanoantagonist demonstrated significantly enhanced blood circulation and peptide stability.
• The nanophase-segregated surface effectively resisted protein adsorption.
• The nanoantagonist successfully blocked PD-1/PD-L1 interactions in vitro and in vivo.
• Enhanced CD8+ T cell-mediated tumor destruction and significant tumor growth inhibition were observed.

Conclusions:

• The developed nanoantagonist offers a promising strategy for overcoming peptide instability in cancer immunotherapy.
• The nanophase-segregated surface design enhances the systemic stability and therapeutic efficacy of peptide antagonists.
• This study presents a novel approach for designing advanced nano-formulations for cancer treatment.